CD8A and neoplasm: How tumor-specific CD8+ tumor-infiltrating lymphocytes (TILs) cope with these challenges and how metabolic reprograming of CD8+ TILs will affect their antitumor performance require further investigations, in order to improve the efficacy of cancer immunotherapy.